Elicio Therapeutics (ELTX) Long-Term Investments (2020 - 2023)

Elicio Therapeutics (ELTX) has 4 years of Long-Term Investments data on file, last reported at $150000.0 in Q1 2023.

• Quarterly Long-Term Investments fell 79.51% year-over-year to $150000.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $150000.0 (down 79.51% YoY) and the FY2022 annual result came in at $874000.0, up 20.89% from the prior year.
• Long-Term Investments slipped to $150000.0 in Q1 2023, from $874000.0 in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $877000.0 in Q1 2021 to a low of $150000.0 in Q1 2023.
• A 4-year average of $762200.0 and a median of $852500.0 in 2021 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2022 — Long-Term Investments rose 20.89% — and 2023, when it slumped 79.51%.
• Tracing ELTX's Long-Term Investments over 4 years: stood at $822000.0 in 2020, then retreated by 12.04% to $723000.0 in 2021, then rose by 20.89% to $874000.0 in 2022, then sank by 82.84% to $150000.0 in 2023.
• The last three Long-Term Investments figures came in at $150000.0 (Q1 2023), $874000.0 (Q4 2022), and $874000.0 (Q3 2022), per Business Quant data.